A carregar...
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
BACKGROUND: Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab (Herceptin), has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers. The activation of alternative growth factor receptors, in particular, the insulin-like growth factor 1 receptor (IGF1R), re...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3974046/ https://ncbi.nlm.nih.gov/pubmed/24571711 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-134 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|